Novavax (NASDAQ:NVAX) shares climbed more than 17% premarket on Monday after the long-awaited approval of its COVID-19 ...

Novavax shares surged more than 17% before the bell on Monday, following the long-delayed approval of its COVID-19 vaccine ...

The appointment of a vocal critic of expedited approvals of vaccines, Vinay Prasad, to run the FDA’s office responsible for ...

The early months of Donald Trump’s presidency have brought sweeping changes to the country’s scientific and medical landscape ...

The U.S. Food and Drug Administration has granted limited approval to Novavax Inc.'s COVID-19 vaccine, restricting its use to ...

Høeg has been skeptical of the safety and value of some vaccines and mandates, raising questions about her approach at the ...

The vaccine will only be available to those at high risk from COVID—excluding those who may need it to protect a relative or ...

Since becoming HHS Secretary, RFK Jr. has been deceptively weaponizing principles of evidence-based medicine against vaccines ...

Novavax Inc. drew retail attention on Friday after receiving a Biologics License Application for its COVID-19 vaccine, ...

This vaccine did previously have emergency approval by the FDA for use but can now be marketed in the U.S. for use, the ...

After a six-week long delay, The Food and Drug Administration (FDA) has finally approved a more traditional protein-based covid vaccine produced by pharmaceutical giant Novavax.

While global giants like Moderna and BioNTech apply mRNA technology to broader disease markets, PRC's mRNA frontrunner is keeping pace. AIM Vaccine (06660.HK), a leading domestic vaccine company, ...